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A B S T R A C T
Purpose
To test whether the prognostic risk of male sex in papillary thyroid cancer (PTC) is determined by
BRAF V600E and can thus be stratiﬁed by BRAF status.
Patients and Methods
We retrospectively investigated the relationship between male sex and clinicopathologic outcomes
in PTC, particularly mortality, with respect to BRAF status in 2,638 patients (male, n = 623; female, n =
2,015) from 11 centers in six countries, withmedian age of 46 years (interquartile range, 35-58 years)
at diagnosis and median follow-up time of 58 months (interquartile range, 26-107 months).
Results
Distant metastasis rates in men and women were not different in wild-type BRAF PTC but were
different in BRAF V600E PTC: 8.9% (24 of 270) and 3.7% (30 of 817; P = .001), respectively. In wild-
type BRAF PTC, mortality rates were 1.4% (ﬁve of 349) versus 0.9% (11 of 1175) in men versus
women (P = .384), with a hazard ratio (HR) of 1.59 (95% CI, 0.55 to 4.57), which remained in-
signiﬁcant at 0.70 (95% CI, 0.23 to 2.09) after clinicopathologic multivariable adjustment. In BRAF
V600E PTC, mortality rates were 6.6% (18 of 272) versus 2.9% (24 of 822) in men versus women
(P = .006), with an HR of 2.43 (95% CI, 1.30 to 4.53), which remained signiﬁcant at 2.74 (95% CI,
1.38 to 5.43) after multivariable adjustment. In conventional-variant PTC, male sex similarly had no
effect in wild-type BRAF patients; mortality rates in BRAF V600E patients were 7.2% (16 of 221)
versus 2.9% (19 of 662) in men versus women (P = .004), with an HR of 2.86 (95% CI, 1.45 to 5.67),
which remained signiﬁcant at 3.51 (95% CI, 1.62 to 7.63) after multivariable adjustment.
Conclusion
Male sex is a robust independent risk factor for PTC-speciﬁc mortality in BRAF V600E patients but
not in wild-type BRAF patients. The prognostic risk of male sex in PTC can thus be stratiﬁed by BRAF
status in clinical application.
J Clin Oncol 36:2787-2795. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Papillary thyroid cancer (PTC) is a common
thyroid malignancy, accounting for 85% to 90%
of all thyroid malignancies, and conventional PTC
(CPTC) is the main histologic variant.1,2 PTC is
generally indolent but can be aggressive, with high
mortality in certain patients.2 Individualized pa-
tient treatment of optimal beneﬁt-harm balance is
the core of management of PTC in clinical
practice. This relies on appropriate stratiﬁcation
of prognostic risk, particularly mortality risk of
patients, which is primarily based on clinico-
pathologic risk factors, including patient age,
tumor size, metastasis, and extrathyroidal exten-
sion. These are well-established independent
mortality risk factors for PTC, which constitute
the cardinal elements in the mortality risk
staging system for PTC of the American Joint
Committee on Cancer (AJCC).3,4 The AJCC risk
staging system has been consistently adapted in
standard clinical practice guidelines for the risk
management of PTC.5-7 Several other mortality
risk staging systems for PTC that have emerged
over the recent decades are all based on these
clinicopathologic risk factors.8,9
A prominent but controversial mortality risk
factor of PTC is male sex. Some early studies
did not show a signiﬁcant effect of male sex on
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PTC-speciﬁc patient survival,10-12 but others did.13 A large study
showed an independent adverse effect of male sex on PTC-speciﬁc
survival,14 whereas a comparably large study conducted at approx-
imately the same time showed no independent effect of male sex.15
Given these and other early controversial data, the AJCC and virtually
all other risk staging systems avoid including sex as a factor in the risk
staging of PTC. However, whether this is the correct practice is
unclear. An increasing number of recent studies have shown an
association between male sex and aggressive PTC tumor behaviors,
such as lymph nodemetastasis,16,17 although some have not.18 Recent
studies have shown an association between male sex and tumor
recurrence19,20 as well as disease-speciﬁcmortality of PTC.21,22 Recent
large entry data analyses have also shown an association betweenmale
sex and PTC-speciﬁc mortality.23-25 The recent results, however, have
again been inconsistent. For example, the effect of male sex remained
after multivariable adjustment for clinicopathologic factors in some
large entry data analyses,26 but it was lost in other large entry data
analyses upon clinicopathologic multivariable adjustment.27 Thus,
whether male sex is a true risk factor and how it can be applied in the
prognostic risk stratiﬁcation of PTC remain controversial.
Like other cancers, PTC is a genetically driven disease, and BRAF
V600E mutation is the most common oncogenic mutation, oc-
curring in 45% of patient cases on average.28 This mutation is as-
sociated with aggressive tumor behaviors,29 disease recurrence,30,31
and disease-speciﬁc mortality of PTC.32 Numerous studies have
documented oncogenic molecular mechanisms of BRAF V600E in
driving the aggressiveness of PTC.33,34 Given these data, in this large
international multicenter study, we tested our hypothesis that BRAF
V600E mutation might constitute a genetic background conferring
male sex mortality risk and that BRAF status could thus differentiate
the prognostic risk of male sex in PTC, reconciling the controversial
clinical results from recent decades.
PATIENTS AND METHODS
Study patients
A total of 2,638 patients with PTC treated with total or near-total
thyroidectomy and therapeutic neck dissection were pooled from 11
medical centers in six countries (Table 1). Pathologic diagnoses of PTC
were established following WHO criteria as documented previously.31,32,35
Postsurgical therapies, including conventional thyrotropin suppression
and radioiodine-131 treatments, were pursued as clinically indicated
following standard practice. Disease recurrence, including local, regional,
and distant recurrences, referred to recurrent or persistent PTC diagnosed
per standard histologic, cytologic, radiographic, or biochemical criteria.5,6
Mortality was deﬁned as PTC-speciﬁc patient death. Follow-up time was
deﬁned as the time period from initial surgical treatment to time of
discovery of disease (for recurrence analyses) or PTC-speciﬁc death (for
mortality analyses) or to the most recent clinical visit for surviving patients
without disease recurrence or death.
Study Design
This was a multicenter retrospective study with institutional review
board approval at each center and, where required, informed patient
consent for the use of thyroid tumor tissue and collection of clinico-
pathologic information as described previously.31,32,35 Genomic DNA
isolated from primary PTC tumors was sequenced at exon 15 of the BRAF
gene to identify BRAF V600E mutation as described previously.31,32 BRAF
V600E mutation status was retrospectively examined solely for this study
and had no impact on the selection of treatment for patients. Data from all
the centers were pooled for the analysis of the relationship between patient
sex and clinical outcomes with respect to BRAF V600E status.
Statistical Analyses
Comparisons of categorical variables were performed using the
Pearson x2 test and Fisher’s exact test when the number of patient cases
was # ﬁve. Wilcoxon Mann-Whitney test for two independent samples in
nonparametric statistics was used to compare the median and interquartile
range (IQR) of continuous variables. Survival probability was estimated by
Kaplan-Meier analysis and log-rank test to compare the differences be-
tween Kaplan-Meier curves of men and women. Cox regression and Cox
proportional hazards analyses were used to compare the univariable and
multivariable effects on disease recurrence and mortality and calculate
hazard ratio (HRs) and 95% CIs. SPSS software (version 17.0; SPSS,
Chicago, IL) was used for these analyses. All P values were two sided, and
a value # .05 was considered signiﬁcant.
RESULTS
Effects of Male Sex on Clinicopathologic Characteristics
of PTC With Respect to BRAF Status
As summarized in Table 2, a total of 2,638 patients with PTC,
of whom 76.4% (2,015) were women and 23.6% (623) were men,
Table 1. Centers, Countries, and Patients Participating in the Study
Medical Center or Country
No. of
Patients
Median (IQR) Age
at Diagnosis (years)
No. (%) of
Male
Patients
Medical center
Johns Hopkins Hospital
(Baltimore, MD)
1,051 46 (36-57) 287 (27.3)
University of Pisa (Pisa, Italy) 189 38 (28-51) 47 (24.9)
University of Perugia
(Perugia, Italy)
117 49 (37-59) 32 (27.4)
University of Milan (Milan,
Italy)
265 45 (36-58) 63 (23.8)
Maria Sklodowska-Curie
Memorial Cancer Centre
and Institute of Oncology
(Gliwice, Poland)
253 47 (35-59) 30 (11.9)
Grifﬁth University (Gold
Coast, Queensland,
Australia)
76 40 (34-56) 20 (26.3)
University of Padua (Padua,
Italy)
135 48 (39-57) 32 (23.7)
University of Pittsburgh
(Pittsburgh, PA)
169 52 (38-63) 42 (24.9)
Hospital La Paz Health
Research Institute
(Madrid, Spain)
66 42 (32-54) 11 (16.7)
University of Sydney
(Sydney, New South
Wales, Australia)
95 44 (34-59) 20 (21.1)
Institute of Endocrinology
(Prague, Czech Republic)
222 47 (31-60) 39 (17.6)
Country
United States 1,220 47 (37-58) 329 (27.0)
Italy 706 45 (34-56) 174 (24.6)
Poland 253 47 (35-59) 30 (11.9)
Australia 171 43 (34-57) 40 (23.4)
Spain 66 42 (32-54) 11 (16.7)
Czech Republic 222 47 (31-60) 39 (17.6)
Overall 2,638 46 (35-58) 623 (23.6)
Abbreviation: IQR, interquartile range.
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were included in the study, with a median age of 46 years (IQR, 35-
58 years) at diagnosis of PTC and a median clinical follow-up time
of 58 months (IQR, 26-107 months). CPTC accounted for 71.8%
(1,893 of 2,638) of the patient cases. Taking advantage of this large
international multicenter cohort, we ﬁrst examined the effect of
male sex on clinicopathologic characteristics of PTC as performed
in previous studies. Compared with female sex, male sex was
associated with a higher prevalence of several high-risk clinico-
pathologic characteristics, including older patient age, larger tu-
mor size, extrathyroidal extension, lymph node metastasis, distant
metastasis, and advanced disease stages of III or IV. These results
were consistent with some previous reports.
The overall prevalence of BRAF V600E mutation was 41.8%
(1,094 of 2,618) and was not different between men and women
Table 2. Demographic Characteristics and Distribution of Clinicopathologic Characteristics of PTC Among Men and Women
Characteristic
No. (%)
PTotal Women Men
All PTCs*
Total patients 2,638 2,015 (76.4) 623 (23.6)
Age at diagnosis, years , .001
Median 46 45 49
IQR 35-58 34-57 38-60
$ 45 1,408 (53.4) of 2,638 1,027 (51.0) of 2,015 381 (61.2) of 623 , .001
Tumor size, cm
Median 1.5 1.5 1.8 , .001
IQR 1.0-2.5 1.0-2.5 1.0-3.2
. 1.0 1,820 (70.0) of 2,601 1,371 (69.0) of 1,987 449 (73.1) of 614 .051
Multifocality 1,000 (38.1) of 2,624 739 (36.9) of 2,004 261 (42.1) of 620 .019
Extrathyroidal extension 668 (25.4) of 2,634 480 (23.9) of 2,012 188 (30.2) of 622 .001
Lymph node metastasis 896 (34.3) of 2,613 632 (31.7) of 1,996 264 (42.8) of 617 , .001
Tumor stage III/IV 614 (23.5) of 2,618 410 (20.5) of 2,000 204 (33.0) of 618 , .001
Distant metastasis 118 (4.5) of 2,615 79 (4.0) of 1,996 39 (6.3) of 619 .014
BRAF mutation 1,094 (41.8) of 2,618 822 (41.2) of 1,997 272 (43.8) of 621 .244
131I treatment† 1,984 (77.5) of 2,559 1,495 (76.4) of 1,957 489 (81.2) of 602 .013
Follow-up time (R), months .003
Median 51 52 46
IQR 23-96 24-99 19-91
Tumor recurrence 423 (16.0) of 2,638 275 (13.6) of 2,015 148 (23.8) of 623 , .001
Follow-up time (M), months .198
Median 58 58 55
IQR 26-107 27-107 24-108
Mortality 58 (2.2) of 2,638 35 (1.7) of 2,015 23 (3.7) of 623 .004
CPTC*
Total patients 1,893 1,440 (76.1) 453 (23.9)
Age at diagnosis, years 1,893 1,440 453 , .001
Median 46 45 49
IQR 35-57 34-57 39-60
$ 45 1,002 (52.9) of 1,893 725 (50.3) of 1,440 277 (61.1) of 453 , .001
Tumor size, cm , .001
Median 1.5 1.5 1.6
IQR 1.0-2.4 1.0-2.2 1.0-3.0
. 1.0 1,241 (66.3) of 1,873 931 (65.2) of 1,428 310 (69.7) of 445 .082
Multifocality* 731 (38.7) of 1,888 540 (37.6) of 1,437 191 (42.4) of 451 .070
Extrathyroidal extension 504 (26.7) of 1,890 356 (24.8) of 1,438 148 (32.7) of 452 .001
Lymph node metastasis 690 (36.9) of 1,872 482 (33.8) of 1,425 208 (46.5) 447 , .001
Tumor stage III/IV 445 (23.7) of 1,881 294 (20.5) of 1,432 151 (33.6) of 449 , .001
Distant metastasis 74 (3.9) of 1,885 46 (3.2) of 1,433 28 (6.2) of 452 .004
BRAF mutation 883 (47.0) of 1,879 662 (46.4) of 1,428 221 (49.0) of 451 .327
131I treatment† 1,418 (76.6) of 1,851 1,061 (75.3) of 1,409 357 (80.8) of 442 .018
Follow-up time (R), months .001
Median 52 54 46
IQR 24-99 24-102 19-90
Tumor recurrence 320 (16.9) of 1,893 199 (13.8) of 1,440 121 (26.7) of 453 , .001
Follow-up time (M), months .134
Median 60 61 57
IQR 27-110 28-110 25-110
Mortality 41 (2.2) of 1,893 23 (1.6) of 1,440 18 (4.0) of 453 .002
Abbreviations: CPTC, conventional papillary thyroid cancer; 131I, radioiodine-131; IQR, interquartile range; M, mortality; PTC, papillary thyroid cancer; R, recurrence.
*Data were frommedical centers 1 to 11 (Data Supplement), with a total of 2,638 patient cases of PTC, including 1,893 CPTCs. Information on tumor size, multifocality,
extrathyroidal extension, lymph nodemetastasis, tumor stage III/IV, distant metastasis, and BRAFmutation wasmissing in 37 and 20, 14 and ﬁve, four and three, 25 and
21, 20 and 12, 23 and eight, and 20 and 14 patient cases in the group of patients with any PTC and the group with CPTC, respectively.
†Data on 131I treatment were from medical centers 1 to 5 and 7 to 11, with a total of 2,562 patient cases, including 1,853 CPTCs, with information missing in three and
two patient cases in the group of patients with any PTC and the group with CPTC, respectively.
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(Table 2). When dividing the entire cohort into wild-type BRAF
and BRAF V600E groups, the effect of male sex on clinicopath-
ologic characteristics, such as extrathyroidal extension, lymph
node metastasis, and stage III to IV, was signiﬁcant in both wild-
type BRAF and BRAFV600E groups (Table 3). A striking exception
was distant metastasis, which is known to be the most robust risk
factor for PTC-speciﬁc mortality; there was no difference in the
distant metastasis rate between men and women with wild-type
BRAF PTC: 4.3% (15 of 347) and 4.2% (49 of 1,161; P = .934),
respectively. In contrast, distant metastasis rates were sharply
different between men and women with BRAF V600E PTC: 8.9%
(24 of 270) and 3.7% (30 of 817; P = .001), respectively. Similar
results were obtained when only CPTC was analyzed (Table 3).
Speciﬁcally, there was no difference in distant metastasis rate
between men and women with wild-type BRAF CPTC: 3.5% (eight
of 229) and 3.0% (23 of 762; P = .717), respectively; however, there
Table 3. Effects of Patient Sex on Clinicopathologic Characteristics of PTC by BRAF Status
Characteristic
Wild-Type BRAF BRAF V600E
No. (%) of Women No. (%) of Men P No. (%) of Women No. (%) of Men P
All PTCs*
Total patients 1,175 (77.1) of 1,524 349 (22.9) of 1,524 822 (75.1) of 1,094 272 (24.9) of 1,094
Age at diagnosis, years , .001 .001
Median 44 47 47 51
IQR 33-55 37-60 35-59 40-60
$ 45 561 (47.7) of 1,175 200 (57.3) of 349 .002 455 (55.4) of 822 180 (66.2) of 272 .002
Tumor size, cm .001 .001
Median 1.5 1.8 1.6 2.0
IQR 0.9-2.5 1.0-3.4 1.1-2.5 1.2-3.0
. 1.0 742 (64.2) of 1,156 232 (67.4) of 344 .267 620 (76.3) of 813 216 (80.6) of 268 .141
Multifocality 412 (35.3) of 1,166 139 (22.9) of 346 .101 318 (38.8) of 820 120 (44.1) of 272 .120
Extrathyroidal extension 191 (16.3) of 1,173 83 (23.8) of 349 .001 284 (34.6) of 821 103 (38.0) of 271 .308
Lymph node metastasis 311 (26.9) of 1,158 138 (39.8) of 347 , .001 312 (38.0) of 820 125 (46.6) of 268 .013
Tumor stage III/IV 166 (14.2) of 1,166 90 (26.0) of 346 , .001 240 (29.4) of 816 113 (41.9) of 270 , .001
Distant metastasis 49 (4.2) of 1,161 15 (4.3) of 347 .934 30 (3.7) of 817 24 (8.9) of 270 .001
131I treatment† 812 (70.7) of 1,148 255 (76.6) of 333 .036 665 (84.1) of 791 232 (86.9) of 267 .267
Follow-up time (R), months .068 .032
Median 58 52 45 34
IQR 25-115 24-98 21-85 15-79
Tumor recurrence 122 (10.4) of 1,175 61 (17.5) of 349 , .001 152 (18.5) of 822 87 (32.0) of 272 , .001
Follow-up time (M), months .238 .705
Median 64 59 52 48
IQR 29-119 26-112 24-93 22-102
Mortality 11 (0.9) of 1,175 5 (1.4) of 349 .384 24 (2.9) of 822 18 (6.6) of 272 .006
CPTC*
Total patients 766 (76.9) of 996 230 (23.1) of 996 662 (75.0) of 883 221 (25.0) of 883
Age at diagnosis, years .003 , .001
Median 44 47 46 50
IQR 34-55 38-60 34-59 40-59
$ 45 365 (47.7) of 766 133 (57.8) of 230 .007 351 (53.0) of 662 143 (64.7) of 221 .002
Tumor size, cm .045 .003
Median 1.3 1.5 1.5 1.8
IQR 0.7-2.0 0.7-2.7 1.1-2.5 1.2-3.0
. 1.0 431 (56.6) of 761 135 (59.7) of 226 .408 496 (75.7) of 655 174 (80.2) of 217 .177
Multifocality 279 (36.5) of 765 89 (39.0) of 228 .482 254 (38.5) of 660 100 (45.2) of 221 .076
Extrathyroidal extension 137 (17.9) of 765 58 (25.2) of 230 .014 216 (32.7) of 661 88 (40.0) of 220 .048
Lymph node metastasis 222 (29.5) of 752 99 (43.4) of 228 , .001 255 (38.6) of 661 108 (49.8) of 217 .004
Tumor stage III/IV 111 (14.6) of 761 58 (24.6) of 228 , .001 180 (27.3) of 659 94 (42.9) of 219 , .001
Distant metastasis 23 (3.0) of 762 8 (3.5) of 229 .717 23 (3.5) of 659 20 (9.0) of 221 .001
131I treatment† 512 (67.7) of 756 167 (74.9) of 223 .041 537 (83.8) of 641 188 (86.6) of 217 .314
Follow-up time (R), months .052 .007
Median 62 55 47 34
IQR 28-120 25-96 22-87 14-84
Tumor recurrence 75 (9.8) of 766 47 (20.4) of 230 , .001 123 (18.6) of 662 74 (33.5) of 221 , .001
Follow-up time (M), months 766 230 .293 662 221 .350
Median 66 62 54 48
IQR 35-124 30-118 26-97 21-107
Mortality 4 (0.5) of 766 2 (0.9) of 230 .626 19 (2.9) of 662 16 (7.2) of 221 .004
Abbreviations: CPTC, conventional papillary thyroid cancer; 131I, radioiodine-131; IQR, interquartile range; M, mortality; PTC, papillary thyroid cancer; R, recurrence.
*Data were frommedical centers 1 to 11 (Data Supplement), with a total of 2,638 patient cases of PTC, including 1,893 CPTCs. Information on tumor size, multifocality,
extrathyroidal extension, lymph nodemetastasis, tumor stage III/IV, distant metastasis, and BRAFmutation was missing in 37 and 20, 14 and ﬁve, four and three, 25 and
21, 20 and 12, 23 and eight, and 20 and 14 patient cases in the group of patients with any PTC and the group with CPTC, respectively.
†Data on 131I treatment were from medical centers 1 to 5 and 7 to 11, with a total of 2,562 patient cases, including 1,853 CPTCs, with information missing in three and
two patient cases in the group of patients with any PTC and the group with CPTC, respectively.
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was a signiﬁcant difference in distant metastasis rate between men
and women with BRAF V600E CPTC: 9.0% (20 of 221) and 3.5%
(23 of 659; P = .001), respectively.
Effects of Male Sex on Recurrence and Mortality of PTC
With Respect to BRAF Status
In the overall analysis of PTC, disease recurrence and patient
mortality rates were 16.0% (423 of 2,638) and 2.2% (58 of 2,638),
respectively, which were all higher in men than women, whether in
the analysis of all PTCs or CPTCs (Table 2). Corresponding HRs
were all signiﬁcant, and they remained signiﬁcant except for
mortality in the analysis of all PTCs after multivariable clinico-
pathologic adjustment for patient age at diagnosis, tumor size,
multifocality, extrathyroidal extension, lymph node metastasis,
and radioiodine-131 treatment (Table 4). These results were
consistent with some previous reports. However, a striking ﬁnding
was the effect of BRAF V600E revealed when the cohort was di-
vided into wild-type BRAF and BRAF V600E groups (Tables 3 and
4). In wild-type BRAF patients, although disease recurrence was
signiﬁcantly higher in men than women in univariable analyses
of either all PTCs or CPTCs (Table 3), this difference became
insigniﬁcant after multivariable clinicopathologic adjustment, re-
sulting in insigniﬁcant HRs (Table 4). There was no difference in
mortality rate betweenmale and female wild-type BRAF patients in
univariable analyses of all PTCs or CPTCs (Table 3), corresponding
to insigniﬁcant HRs, which remained insigniﬁcant after multi-
variable adjustment (Table 4). In striking contrast, in patients with
BRAF V600E PTC, disease recurrence was signiﬁcantly higher in
men versus women, whether in the analysis of all PTCs or CPTCs:
32.0% (87 of 272) versus 18.5% (152 of 822; P , .001) in the
former and 33.5% (74 of 221) versus 18.6% (123 of 662; P, .001)
in the latter (Table 3); these corresponded to HRs of 1.89 (95% CI,
1.45 to 2.46; P , .001) and 2.04 (95% CI, 1.53 to 2.73; P , .001),
respectively, which remained signiﬁcant at 1.50 (95% CI, 1.14 to
1.98; P = .004) and 1.54 (95% CI, 1.13 to 2.08; P = .006), re-
spectively, after multivariable adjustment (Table 4). Mortality rates
in BRAFV600E–positive patients were 6.6% (18 of 272) versus 2.9%
(24 of 822) in men versus women (P = .006) in the analysis of all
PTCs and 7.2% (16 of 221) versus 2.9% (19 of 662; P = .004) in the
analysis of CPTCs (Table 3); these corresponded to HRs of 2.43
(95% CI, 1.30 to 4.53; P = .005) and 2.86 (95% CI, 1.45 to 5.67; P =
.003) in univariable analyses, which remained robustly signiﬁcant at
2.74 (95% CI, 1.38 to 5.43; P = .004) and 3.51 (95% CI, 1.62-7.63;
P = .002), respectively, upon multivariable adjustment (Table 4).
When dividing the cohort into four groups (women with wild-
type BRAF, men with wild-type BRAF, women with BRAF V600E
mutation, and men with BRAF V600E mutation; Table 5), there was
no difference between women and men with wild-type BRAF, again
demonstrating no effect of male sex in wild-type BRAF patients.
Compared with women with wild-type BRAF, women with BRAF
V600E mutation had a signiﬁcant unadjusted HR of mortality, but
this signiﬁcance was completely lost uponmultivariable adjustment,
suggesting that female sex and BRAF V600E mutation had no in-
dependent interaction on the mortality. In contrast, compared with
women with wild-type BRAF, men with BRAF V600E mutation had
a robust unadjusted HR of mortality, which, upon multivariable
analysis, only marginally lost signiﬁcance in the overall analysis of all
PTCs (P = .079) but remained signiﬁcant in the analysis of CPTCs
(P = .009). The synergy index of mortality risk for the interaction
between male sex and BRAF V600E was 2.40 (95% CI, 1.00 to 5.74;
P = .050) for all PTCs and 2.80 (95% CI, 1.19 to 6.59; P = .018) for
CPTCs. Thus, the interaction between male sex and BRAF V600E
had an independent effect on mortality, particularly robustly in
CPTC, the most common variant of PTC in which BRAF V600E is
a primary oncogene.
Effect of Male Sex on PTC-Specific Survival Curves of
Patients With Respect to BRAF Status
As shown in Figure 1, Kaplan-Meier analyses showed no
difference in disease-speciﬁc survival curves between men and
women with wild-type BRAF PTC, whether in the analysis of all
PTCs (P = .387; Fig 1A) or CPTCs only (P = .521; Fig 1B); the two
lines remained ﬂat without separation. In striking contrast, in
BRAF V600E patients, the disease-speciﬁc survival curve sharply
declined in men, whereas the curve for women remained ﬂat,
resulting in a signiﬁcant separation of the two curves, whether in
the analysis of all PTCs (P = .004; Fig 1C) or CPTCs only (P = .002;
Fig 1D). These results showed a BRAF V600E–dependent effect of
male sex on disease-speciﬁc survival of patients with PTC.
DISCUSSION
Early studies on the mortality risk of male sex in PTC were con-
troversial.10-15 Studies in recent years have increasingly shown an
adverse effect of male sex on the prognosis of PTC.16,17,19-25 However,
controversy still exists, as exempliﬁed by the fact that the mortality
risk of male sex remained after multivariable clinicopathologic ad-
justment in some large entry data analyses26 but was lost in other large
entry data analyses uponmultivariable adjustment.27 Standard clinical
guidelines,5-7 the AJCC system,3,4 and other risk staging models8,9
virtually uniformly avoid including male sex as a mortality factor in
the risk stratiﬁcation of PTC, leaving unresolved the decades-long
dilemma of whether male sex is a mortality risk for PTC.
We performed here a large international multicenter study to
investigate further the prognostic risk of male sex in PTC, particularly
mortality risk. In the overall analysis, irrespective of BRAF status, we
found a signiﬁcant association between male sex and poor clinico-
pathologic characteristics of PTC. Male sex also had an adverse effect
on disease recurrence and disease-speciﬁc mortality, although the
effect on the latter was not independent. We additionally examined
only CPTC and made similar observations. These results were
consistent with some previous reports,13,14,16,17,19-25 providing fur-
ther evidence suggesting that male sex is a risk factor for poor clinical
outcomes of PTC, but it may be so only under certain circumstances.
Indeed, a striking ﬁnding in our study was the differentiating
role of BRAF V600E in the effect of male sex on clinical outcomes
of PTC. In wild-type BRAF patients, male sex was a signiﬁcant risk
factor for disease recurrence in univariable but not multivariable
analyses. Male sex had no effect at all on mortality in wild-type
BRAF patients, whether in univariable or multivariable analyses.
Thus, male sex is not an independent risk factor for poor clinical
outcomes of wild-type BRAF PTC. In contrast, in BRAF V600E
patients, male sex was strongly and independently associated with
jco.org © 2018 by American Society of Clinical Oncology 2791
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both disease recurrence and PTC-speciﬁc mortality, particularly
the latter, either in univariable or multivariable analyses. All these
effects of male sex were similarly observed when only CPTC, the
most common and homogenous variant of PTC, was analyzed. In
fact, the effects of male sex were generally even more robust in
BRAFV600E CPTC. Thus, BRAFV600E conferred an independent
risk of male sex for poor clinical outcomes, particularly disease-
speciﬁc mortality, in PTC.
It is intriguing that even in patients with wild-type BRAF PTC,
male sex was associated with several aggressive tumor behaviors,
such as lymph node metastasis and extrathyroidal extension.
However, these tumor behaviors were mild in wild-type BRAF PTC
when compared with those in BRAF V600E PTC; unlike in the
latter, they did not progress to mortality in the former. Similarly,
unlike in BRAF V600E PTC, recurrent disease of wild-type BRAF
PTC, which was associated with male sex only in univariable
analysis but not in multivariable analysis, was also a mild condition
in that it also did not progress to mortality. Thus, male sex is an
independent risk factor for poor clinical outcomes, particularly
mortality, in BRAF V600E PTC but not in wild-type BRAF PTC. In
fact, there was an independent interaction between male sex and
BRAF V600E in affecting PTC-speciﬁc mortality. These ﬁndings
may explain and reconcile the controversies of previous studies on
the prognostic role of male sex in PTC; depending on the
Table 5. PTC-Speciﬁc Mortality, Deaths per 1,000 Person-Years, and HRs
BRAF Status
Mortality
Deaths per 1,000 Person-Years
(95% CI)
Unadjusted Adjusted*
No. (%) P HR (95% CI) P HR (95% CI) P
All PTCs
Negative
Female 11 (0.9) of 1,175 — 1.42 (0.78 to 2.56) 1.00 1.00
Male 5 (1.4) of 349 .424 2.29 (0.95 to 5.51) 1.59 (0.55 to 4.58) .39 0.70 (0.23 to 2.10) .526
Positive
Female 24 (2.9) of 822 .001 5.28 (3.54 to 7.88) 3.55 (1.73 to 7.26) .001 0.58 (0.25 to 1.38) .221
Male 18 (6.6) of 272 , .001 11.95 (7.53 to 18.97) 8.41 (3.97 to 17.83) , .001 2.10 (0.92 to 4.84) .079
CPTC
Negative
Female 4 (0.5) of 766 — 0.75 (0.28 to 1.99) 1.00 1.00
Male 2 (0.9) of 230 .626 1.32 (0.33 to 5.30) 1.73 (0.32 to 9.45) .527 0.86 (0.15 to 4.90) .862
Positive
Female 19 (2.9) of 662 , .001 5.00 (3.19 to 7.85) 6.35 (2.14 to 18.80) .001 1.19 (0.35 to 4.06) .775
Male 16 (7.2) of 221 , .001 13.00 (7.96 to 21.22) 17.75 (5.92 to 53.28) , .001 4.89 (1.48 to 16.13) .009
Abbreviations: CPTC, conventional papillary thyroid cancer; HR, hazard ratio; PTC, papillary thyroid cancer.
*Adjusted for patient age at diagnosis, tumor size, multifocality, extrathyroidal extension, lymph node metastasis, and radioiodine-131 treatment.
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Fig 1. Disease-speciﬁc Kaplan-Meier survival
curves in men and women with wild-type BRAF or
BRAF V600E papillary thyroid cancer (PTC). Com-
parison of PTC-speciﬁc survival curves between
men and women with (A) wild-type BRAF in the
analysis of patients with any PTC (all PTCs), (B) wild-
type BRAF in the analysis of only patients with
conventional PTC (CPTC), (C) BRAF V600E in the
analysis of patients with any PTC, and (D) BRAF
V600E in the analysis of only patients with CPTC.
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prevalence and distribution of BRAF V600E–positive patient cases
among patient cohorts in different studies, results may vary.
It is also intriguing to see a strong association between male
sex and distant metastasis in BRAF V600E PTC but not in wild-
type BRAF PTC. This is a pathologic explanation for the mortality
risk of male sex in BRAF V600E PTC, because distant metastasis is
the most robust risk factor for PTC-speciﬁc mortality; distant
metastasis may practically be treated as equivalent to mortality.
This ﬁnding is again consistent with the concept that male sex is
a strong risk factor for disease aggressiveness of BRAF V600E PTC.
The molecular mechanism for male sex–associated risk for the
poor prognosis of PTC with BRAF V600E remains to be elucidated.
BRAF V600E has been widely shown to be a prominent oncogene
driving aggressive pathogenesis of PTC33 and poor clinical
outcomes.30-32 It is plausible to speculate that the BRAF V600E/
mitogen-activated protein kinase (MAPK) pathway might interact
with certain male sex–speciﬁc molecular or cellular processes to
promote aggressiveness of PTC. It has been recently demonstrated
that BRAF V600E is a robust driver of the mutant TERT through
a novel MAPK/FOS/GA-binding protein (GABP) pathway.36 In this
process, once phosphorylated and activated by the MAPK pathway,
FOS as a novel transcriptional factor of GABPB binds and activates
the promoter of GABPB, promoting its expression. Increased
GABPB forms a complex with GABPA to activate speciﬁcally the
mutant TERT promoter, resulting in increased TERT expression,
leading to aggressiveness of thyroid cancer. FOS thus plays a key role
in functionally bridging the two oncogenes in cooperatively pro-
moting oncogenesis, in which BRAF V600E is the primary driver.
This may be a mechanism for the male sex–associated mortality risk
in BRAF V600E PTC, particularly given the fact that BRAF V600E
and TERT promoter mutations frequently coexist, cooperatively
promote the recurrence andmortality of PTC, and occur more often
in men than women.37-39 It is possible that BRAF V600E may drive
other male sex–related genetic or epigenetic aberrations in pro-
moting PTC aggressiveness yet to be deﬁned. The prevalence of
BRAF V600E was not signiﬁcantly different between women and
men, suggesting that the prevalence per se cannot explain male
sex–associated mortality risk.
Patient age at diagnosis of disease is a strong mortality risk for
PTC. We recently demonstrated that BRAF V600E could
differentiate patient age–associated mortality risk of PTC;
patient age was a signiﬁcant independent mortality risk in
BRAF V600E PTC but not wild-type BRAF PTC.35 Our study
provides another example that BRAF V600E is a genetic
background underpinning the mortality risk of some classic
clinical factors of PTC.
In summary, in this large international multicenter study, we
for the ﬁrst time to our knowledge demonstrate that male sex is an
independent risk factor for poor clinical outcomes of PTC, par-
ticularly mortality, in BRAF V600E patients but not in wild-type
BRAF patients. This study helps reconcile previous controversial
ﬁndings on the role of male sex in the prognosis of PTC and
supports its use as an independent risk factor in clinical risk
staging, particularly mortality risk, for patients with BRAF V600E
PTC. In contrast, male sex is not an independent prognostic risk in
patients with wild-type BRAF PTC.
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